Improvements in current treatments and emerging therapies for adult obstructive sleep apnea

Neil Freedman

Address: Northshore University Health System, 2151 Waukegan Road, Bannockburn, IL 60015, USA
Email: neilfreedman@comcast.net

F1000Prime Reports 2014, 6:36 (doi:10.12703/P6-36)
All F1000Prime Reports articles are distributed under the terms of the Creative Commons Attribution-Non Commercial License (http://creativecommons.org/licenses/by-nc/3.0/legalcode), which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The electronic version of this article is the complete one and can be found at: http://f1000.com/prime/reports/m/6/36

Abstract
Obstructive sleep apnea (OSA) is common and is associated with a number of adverse outcomes, including an increased risk for cardiovascular disease. Typical treatment approaches, including positive airway pressure, oral appliances, various upper airway surgeries, and/or weight loss, can improve symptoms and reduce the severity of disease in select patient groups. However, these approaches have several potential limitations, including suboptimal adherence, lack of suitability for all patient groups, and/or absence of adequate outcomes data. Emerging potential therapeutic options, including nasal expiratory positive airway pressure (PAP), oral negative pressure, upper airway muscle stimulation, and bariatric surgery, as well as improvements in existing treatments and the utilization of improving technologies are moving the field forward and should offer effective therapies to a wider group of patients with OSA.

Introduction
OSA is characterized by intermittent partial or complete occlusions of the upper airway (termed hypopneas and apneas, respectively) due to a combination of excess tissue and inappropriate upper airway muscle relaxation. OSA is a common disorder, affecting 5% to 10% of middle-aged adults and up to 20% of adults over 65 years of age [1]. Untreated OSA may cause, or has been associated with, several adverse outcomes, including daytime sleepiness, increased risk for motor vehicle accidents, increased risk for cardiovascular disease, depression, and poorer quality of life [2-5]. The prevalence of adverse outcomes is typically dose-dependent in the context of an increased number of apneas and hypopneas per hour of sleep, as reflected in the apnea/hypopnea index (AHI), and the severity of oxygen desaturation.

Typical treatments for patients with OSA include PAP therapy, oral appliances (those that advance the mandible and those that prevent relapse of the tongue), various surgeries that modify the upper airway, and/or weight loss (dietary, pharmacologically, and surgically induced). This article will initially review PAP therapy, its limitations in clinical practice, and the potential use of improved technology and telemedicine to improve PAP adherence. The discussion will also cover several emerging technologies and improvements in existing therapies that may enhance and improve treatment for patients with OSA in the near future.

Positive airway pressure therapy
Continuous positive airway pressure (CPAP) therapy is the most common treatment used across the spectrum of OSA severity and is the recommended initial treatment for most patients with moderate to severe OSA [6]. With adequate patient adherence, CPAP consistently improves symptoms of daytime sleepiness attributable to OSA in those with moderate to severe disease and may improve blood pressure and other cardiovascular outcomes [2,4,5,7].

Although many individuals have excellent adherence to CPAP therapy across all patients for whom it is prescribed, adherence is suboptimal, and overall adherence with CPAP therapy averages approximately 50% (range of 30% to 70%) [1]. Interventions demonstrated to improve
initial CPAP adherence include education (increased office visits, pamphlets, group meetings, and phone calls), heated humidification, and cognitive behavioral therapy added to education [6,8]. These interventions have been demonstrated to improve adherence to one degree or another in many, but not all, patients in several short-term studies. Advanced technology PAP devices, such as autoPAP (APAP), bilevel therapies, and expiratory relief devices, have not been shown to consistently improve adherence in patients who are CPAP-naïve or in patients who have been intolerant to standard CPAP therapy [9-12]. Although various approaches to treatment and advancements in technology have evolved to improve adherence, compliance with CPAP therapy has remained relatively unchanged over time [13].

One area of expanding technology related to PAP therapy that has received little research attention involves the use of PAP device-generated adherence data to improve patient outcomes. Most current PAP devices measure the adequacy of control of OSA by using manufacturer-specific propriety algorithms to define OSA events and in some cases to respond and resolve abnormal breathing events. This information is available from multiple sources and can be accessed from the PAP device, in-office software extracted from a data card, and/or cloud-based data sources.

Although the data generated by these devices can reliably track PAP nightly usage, these propriety algorithms have several potential limitations, including the absence of standard definitions for respiratory events and leak tracking, which make it difficult to interpret and compare information between manufacturers and standardize approaches to therapy [14]. There are currently only a few studies validating the various PAP data outputs compared with the standard in-lab polysomnography definitions of respiratory events and these results are exclusive to the specific devices and software studied in those trials [15-17]. Despite these potential limitations, several randomized controlled studies have used the PAP-generated adherence data from several devices and manufacturers to track adherence and the efficacy of therapy in unattended settings, and the majority of these studies demonstrated outcomes similar to those of CPAP therapy determined by a formal in-lab titration study [12,18-20].

Given the expanding role of telehealth and shifts toward shared risk- and population-based models of health care, research should focus on the use of PAP-generated adherence data to improve PAP compliance and other OSA-related outcomes. Currently, the role of online PAP adherence monitoring and other telemedicine technologies to improve outcomes remains unclear [21]. A study by Fox and colleagues [22] did demonstrate a trend toward improved adherence in a group of patients monitored via online compliance tracking compared with usual care, but the outcomes in both the intervention and control groups demonstrated suboptimal compliance compared with historic controls. More research will be required to make this approach to therapy a reality. In addition to research, interventions that will be required to enhance PAP treatment using PAP output technology should include the following:

a) Standardization of respiratory event definitions between manufacturers as well as validation of the device outputs compared with the gold standard, polysomnography.

b) Improved access to PAP adherence data for front-line providers, including determining ways to more easily integrate PAP adherence data into the various electronic medical record software programs.

c) Education of non-sleep specialists on interpretation of the available adherence information. Given the limited time that most primary care providers have to spend with patients, thought from a manufacturer’s standpoint should be focused on developing easy-to-interpret reports that use algorithms incorporating nightly adherence data, AHI, and leak data into an output that would indicate adequate or inadequate therapy and potential interventions to improve problems. These data would need to be easily accessible to the providers and patients and could potentially be accessed at the point of care via a smart phone-based application or web-based data warehouse.

d) Expansion of telehealth utilization by health-care systems and payers to monitor compliance on-line and develop chronic disease management programs for early intervention of patients with OSA, similar to current programs for asthma and diabetes mellitus management [23].

**Improvements in non-continuous positive airway pressure therapies and emerging treatments for obstructive sleep apnea**

As reviewed previously, despite advancements in PAP technology, many patients with OSA are unable or unwilling to tolerate this therapy; thus, alternative therapies may need to be considered. Typical alternative treatments include oral appliances, weight loss, and/or upper airway surgeries. Emerging therapies that may offer novel treatment approaches include nasal expiratory positive airway pressure (nEPAP), oral negative pressure devices, bariatric surgery, and upper airway muscle stimulation.
Oral appliances

Oral appliances are dental devices that improve OSA by maintaining the patency of the posterior pharynx. These devices are typically fit by a qualified dentist and maintain pharyngeal patency by advancing the mandible forward (mandibular repositioning appliances) or maintaining the tongue in an anterior position (tongue-retaining devices) or both. Oral appliances are typically indicated for patients with mild to moderate OSA and for patients with severe OSA who are intolerant or choose not to use CPAP therapy [24]. More recent data demonstrate that a trial of this approach to therapy may also be reasonable for patients with more severe disease (AHI >30 events per hour) [25]. In general, CPAP is more effective at resolving OSA events and improving oxygen saturations, although oral appliances tend to improve symptoms of daytime sleepiness to a similar degree as CPAP [26]. The impact of oral appliance therapy on hypertension, other cardiovascular outcomes, and mortality is not clear [27].

Despite the effectiveness of oral appliance therapy in mitigating OSA in certain patient groups, this approach to therapy has been limited by several factors, including cost, difficulty in predicting success or tolerability prior to initiating therapy, and the inability to monitor compliance with treatment. Recent advances in technology may improve some of these limitations, specifically the ability to predict therapeutic success prior to initiating treatment and compliance monitoring.

Typical predictors of success with oral appliances include less severe disease, younger age, lower body mass index, smaller neck circumference, and those with more positional (supine-dependent) OSA. Despite these predictors, the ability to accurately predict success with OA therapy prior to initiating treatment is approximately 50% of unselected patients in clinical practice [28]. Early studies have suggested that success with oral appliance therapy could be better predicted by using various technologies, although these interventions have yet to be widely adapted to clinical practice [29]. Recently, data have demonstrated that oral appliance therapy success can be accurately predicted in the majority of patients during a single night polysomnography by using a remotely controlled mandibular positioner (MATRx; Zephyr Sleep Technologies, Calgary, Canada) [30]. Remmers and colleagues [30] prospectively studied 67 predominantly obese, male patients with mild to severe OSA (mean AHI of 25.2 ± 14.8) and demonstrated that a successful oral appliance titration could be achieved in 87% of the patients. In this group of patients, the average effective target protrusion position was 68% of the maximum mandibular protrusion range. In general, the remotely controlled titration was well tolerated by patients with minimal sleep disruption related to appliance adjustments during the study. Although this approach may prove useful in determining an effective oral appliance prescription and avoid the current trial-and-error process to determine a therapeutic oral appliance prescription, further studies will be required to determine the effectiveness of this approach in clinical practice.

Another major limitation to expanding the use of oral appliance therapy has been the inability to objectively monitor compliance with treatment. Recent studies have demonstrated potential advancements in this area as well [31,32]. Dieltjens and colleagues [31] studied 51 men with mild to moderate OSA who were treated with oral appliance therapy over the course of 1 year. Compliance with therapy was objectively monitored by using a thermal sensing device embedded in the oral appliance. Regular use, defined as at least 4 hours per night on 70% of the nights, was observed in 83% of the patients over the course of the year. There was high agreement between subjective and objective compliance over the course of the study, and subjective compliance was typically overestimated by 30 minutes per night. Although these results appear promising, larger studies will need to be performed to confirm these findings, and reimbursement strategies will need to be developed to cover the cost of these technologies in clinical practice [33]. Additional advancements that could help expand the use of oral appliance therapy may include the ability of oral appliances to autotitratare on a night-to-night basis and the ability of these devices to transfer objectively monitored compliance data to cloud-based technologies so providers could monitor treatment efficacy in real time.

Nasal expiratory positive airway pressure

Nasal expiratory resistive devices are another potential treatment that has been introduced as an alternative to PAP therapy for OSA. These disposable adhesive devices are placed over the nostrils and increase resistance to flow during exhalation while not adversely affecting flow during inhalation, thus increasing upper airway patency by creating expiratory positive airway pressure (EPAP).

Initial small studies in patients with mild to moderate OSA demonstrated a significant reduction in the AHI and oxygen desaturation index, and the greatest benefit was observed in those with more mild disease [34,35]. Berry and colleagues [36] performed a larger randomized controlled trial (n = 250) in a group of treatment-naïve patients with predominantly mild OSA. Patients were randomly assigned to either treatment with nEPAP (Provent; Theravent Inc., San Jose, CA, USA) or sham...
In summary, the role of this technology in the treatment of OSA is evolving. Oral pressure therapy may be a reasonable alternative treatment to PAP therapy for adults with mild to moderate disease. The treatment is contraindicated in patients with advanced periodontal disease or loose teeth, nasal obstruction, or asthma or other advanced lung diseases, patients with a history of pneumothorax, and those under the age of 18. Because successful treatment with oral pressure therapy is not predictable prior to treatment, objective testing on therapy is necessary to document efficacy. Additional research is necessary to better define the appropriate populations for treatment and to determine appropriate algorithms for adequate follow-up.
Surgery
Various surgical approaches have been used as treatments for OSA. Aside from tracheostomy and maxillo-mandibular advancement for patients with severe OSA who have failed a trial of CPAP therapy, the application of other upper airway surgeries for the routine treatment of OSA is limited because of a paucity of rigorous data evaluating most of these procedures [42]. In general, any upper airway surgical procedure should be considered only after a trial of CPAP or oral appliance therapy (or both) has been unsuccessful. Despite the limitations regarding procedures that surgically modify the upper airway, recent data support two surgical approaches that may offer viable alternatives to CPAP and oral appliance therapy.

Upper airway muscle stimulation therapy
The physiology of OSA is characterized by recurrent collapse of the upper airway that is due, in part, to a reduction in pharyngeal dilator muscle tone. Early studies in animals and humans demonstrated that electrical stimulation of the hypoglossal nerve could result in improved upper airway patency via stimulation of the genioglossus muscle, resulting in protrusion of the tongue [43]. Since these early feasibility studies, several companies have developed hypoglossal nerve stimulation (HGNS) devices. The Inspire HGNS device (Inspire Medical Systems, Maple Grove, MN, USA) has the most supporting data and is currently undergoing review by the US Food and Drug Administration. This device has a neurostimulator that is implanted under the skin in the upper chest (similar to a cardiac pacemaker), a stimulation electrode placed on the hypoglossal nerve, and a sensing lead that is placed between the internal and external intercostal muscles to detect ventilatory effort. The device is activated prior to bedtime and deactivated in the morning after awakening.

A recently published randomized controlled trial followed by a prospective cohort study evaluated 126 overweight, middle-aged, predominantly male patients with moderate to severe OSA who were previously intolerant to CPAP therapy [44]. The data demonstrated that the Inspire HGNS device significantly reduced the AHI by 68% (AHI 29.3 to 9 events per hour) and improved daytime sleepiness and quality of life during the initial randomized phase, and significant improvements were maintained at the 12-month follow-up. The device was generally well tolerated, and serious adverse events (one cardiac death felt not to be related to the device and one device requiring removal) were observed in less than 2% of the participants. Less severe device-related events included temporary tongue weakness after surgery (18%), tongue soreness (21%), and surgical site pain (40%). Permanent tongue weakness was not observed in any of the participants during the study. Only two study participants required repositioning and fixation of the device.

Not all HGNS devices have proven to impart clinical benefits. The Apnex HGNS device (Apnex Medical, St. Paul, MN, USA) demonstrated improvements in OSA severity and daytime symptoms in an initial smaller group of patients with predominantly severe OSA [45], but the follow-up pivotal phase 3 clinical trial was terminated after the device failed to achieve its primary outcome (ClinicalTrials.gov number NCT01446601). Finally, another HGNS device (Aura6000 System; ImThera, San Diego, CA, USA) is currently approved for use in Europe and is being evaluated in clinical trials prior to approval in the US.

These data demonstrate that HGNS therapy may offer an effective therapy for carefully selected overweight patients with moderate to severe OSA who are intolerant to CPAP therapy [46]. Further study is required to identify the best device, better define suitable candidates, and determine the cost-effectiveness for this type of therapy.

Bariatric surgery
OSA is associated with obesity, and an elevated body mass index is an independent risk factor for OSA in patients under the age of 60. Several studies have demonstrated that dietary weight loss is associated with significant improvements in OSA as measured by reductions in the AHI [47-49]. Unfortunately, as would be expected, most studies show that patients typically achieve only modest reductions in weight with diet and behavioral counseling alone and that clinically significant residual OSA persists in most patients.

Surgical weight loss via various bariatric procedures has been associated with even greater reductions in weight as well as improvements in OSA. In general, there are dose-dependent improvements in OSA for a given amount of weight loss, although most patients, regardless of the method of surgical weight loss, have residual OSA despite significant reductions in weight [50-53]. Thus, based on the current data, bariatric surgery may lead to long-term improvements in OSA severity, although many patients may be left with significant residual OSA requiring other treatments.

In summary, although significant weight loss can lead to improvements in OSA, the data demonstrate that the majority of patients do not achieve or maintain enough weight loss to resolve their OSA and thus will require ongoing treatment. Given this information, weight loss
via diet or bariatric procedures should not be considered a primary therapy for OSA across the spectrum of disease severity and should be recommended as a secondary therapy or intervention that supplements a primary treatment such as CPAP or oral appliances. Finally, even for those patients who are able to lose a significant amount of weight and maintain that weight loss over time, objective sleep study testing should be performed to assess for residual disease prior to discontinuing CPAP therapy.

**Summary**

OSA is common and untreated disease is associated with several adverse consequences. Unfortunately, although currently available treatments can improve these outcomes, compliance with CPAP therapy is suboptimal for many patients and other currently available standard therapies have several limitations. Emerging therapies, improvements in existing treatments, and the utilization of improving technologies are moving the field forward and should offer effective interventions to a wider group of patients with OSA. The current data support the following:

a) PAP therapy is currently the mainstay of treatment across the spectrum of disease and should be considered the first-line therapy for most patients with OSA. Since adherence with PAP therapy remains suboptimal for many patients, future research needs to focus on processes that increase adherence through improved patient and provider education as well as the development and better utilization of advancing technologies.

b) Oral appliance therapy is indicated primarily for patients with mild to moderate OSA, and recent data demonstrate efficacy in some patients with more severe disease. The role of oral appliance therapy will expand as newer technologies improve the ability to predict success with treatment prior to initiating therapy as well as monitor compliance with ongoing treatment.

c) Weight loss, through either diet or bariatric procedures, should be recommended for all OSA patients who are overweight or obese. Most patients will have clinically significant residual OSA despite substantial weight loss. Thus, follow-up testing is recommended after significant weight loss has been achieved to objectively determine the need for ongoing OSA therapy.

d) Various upper airway surgeries can be considered for patients who cannot tolerate CPAP or oral appliance therapy, although the current data supporting various procedures are limited and more information is required to determine which procedures may benefit certain patient groups.

e) Hypoglossal nerve stimulation therapy may offer an alternative treatment for overweight patients with moderate to severe OSA. It currently remains investigational in the US, and further research is required to better identify appropriate patient groups, the best device, potential long-term side effects, and cost-effectiveness compared with standard treatments.

f) nEPAP devices can improve OSA severity and daytime symptoms, although the best results are typically observed in patients with more mild disease. This form of treatment may be considered an alternative to CPAP or oral appliance therapy in patients with less severe uncomplicated disease and should not be used in patients with severe OSA, significant oxygen desaturation, nasal occlusion, or comorbid lung disease or in patients with baseline hypercapnea.

g) Oral negative pressure therapy is a reasonable alternative treatment to PAP therapy for those with uncomplicated mild to moderate disease. Objective testing on therapy is necessary to document efficacy, as successful treatment with this therapy is difficult to predict prior to initiating treatment. Additional research is required to better define the appropriate populations for treatment and to determine appropriate algorithms for adequate follow-up.

h) Finally, future research should also expand the use of genomics, various biomarkers, and bioinformatics to better identify patient groups who may be at lower risk for adverse outcomes or will not benefit from specific OSA therapies (or both).

**Abbreviations**

AHI, apnea/hypopnea index; CPAP, continuous positive airway pressure; FRC, functional residual capacity; HGNS, hypoglossal nerve stimulation; nEPAP, nasal expiratory positive airway pressure; OSA, obstructive sleep apnea; PAP, positive airway pressure.

**Disclosures**

The author declares that he has no disclosures.

**References**

1. Jordan AS, McSharry DG, Malhotra A: Adult obstructive sleep apnoea. Lancet 2014, 383:736-47.

2. Gottlieb DJ, Craig SE, Lorenzi-Filho G, Heeley E, Redline S, McEvoy RD, Durán-Cantolla J: Sleep Apnea Cardiovascular Clinical Trials: Current Status and Steps Forward: The International Collaboration of Sleep Apnea Cardiovascular Trials. Sleep 2013, 36:975-80.

3. Campos-Rodriguez F, Martínez-García MA, Martínez M, Durán-Cantolla J, La Peña Md, Masdeu MJ, Gonzalez M, Campo Fd, Gallego I, Marin JM, Barbe F, Montserrat JM, Farre R: Association between obstructive
sleep apnea and cancer incidence in a large multicenter Spanish cohort. Am J Respir Crit Care Med 2013, 187:99-105.

4. Martinez-Garcia M, Capote F, Campos-Rodríguez F, Lloberes P, Díaz de Atauri MJ, Somoza M, Masa JF, González M, Sacristán L, Barbé F, Durán-Cantolla J, Aizpuru F, Mañas E, Barreiro B, Mosteiro M, Cebrián JJ, La Peña M de, García-Río F, Maimó A, Zapater J, Hernández C, Grau SanMartí N, Montserrat JM: Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA 2013, 310:2407-15.

5. Sánchez-de-la-Torre M, Campos-Rodríguez F, Barbé F: Obstructive sleep apnoea and cardiovascular disease. Lancet Respir Med 2013, 1:61-72.

6. Epstein LJ, Kristo D, Strollo PJ, Friedman N, Malhotra A, Patsil SP, Ramar K, Rogers R, Schwab RJ, Weaver EM, Weinstein MD: Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009, 5:263-76.

7. Montesi SB, Edwards BA, Malhotra A, Bakker JP: The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med 2012, 8:587-96.

8. Wozniak DR, Lasserson TJ, Smith I: Educational, supportive and behavioural interventions to improve usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev 2014, 1:CD007736.

9. Blau A, Minx M, Peter JG, Glos M, Penzel T, Baumann G, Fietze I: Auto bi-level pressure relief-PAP is as effective as CPAP in OSA patients—a pilot study. Sleep Breath 2012, 16:773-9.

10. Smith I, Lasserson TJ: Pressure modification for improving usage of continuous positive airway pressure machines in adults with obstructive sleep apnoea. Cochrane Database Syst Rev 2009, CD003531.

11. Bakker JP, Marshall NS: Flexible pressure delivery modification of continuous positive airway pressure for obstructive sleep apnea does not improve compliance with therapy: systematic review and meta-analysis. Chest 2011, 139:322-30.

12. Rosen CL, Auckley D, Breslin K, Coburn-Kraft D, Korda A, Krieger H, Multicenter Z: A multisite randomized trial of portable sleep studies and positive airway pressure auto- titration versus laboratory-based polysomnography for the diagnosis and treatment of obstructive sleep apnea: the HomePAP study. Sleep 2012, 35:577-67.

13. Weaver TE: Don’t start celebrating—CPAP adherence remains a problem. J Clin Sleep Med 2013, 9:551-2.

14. Schwab RJ, Badr SM, Epstein LJ, Gay PC, Gozal D, Kohler M, Lévy P, Malhotra A, Phillips BA, Rosen IM, Strohl KP, Strollo PJ, Weaver EM, Weaver TE: An official American Thoracic Society statement: continuous positive airway pressure adherence tracking systems. The optimal monitoring strategies and outcome measures in adults. Am J Respir Crit Care Med 2013, 188:613-20.

15. Berry RB, Kushida CA, Kryger MH, Soto-Calderon H, Staley B, Kuna ST: Respiratory event detection by a positive airway pressure device. Sleep 2012, 35:361-7.

16. Ueno K, Kasai T, Brewer G, Takaya H, Maeno K, Kasagi S, Kawanami F, Ishiwata S, Narui K: Evaluation of the apnoea-hypopnoea index determined by the S8 auto-CPAP, a continuous positive airway pressure device, in patients with obstructive sleep apnea-hypopnea syndrome. J Clin Sleep Med 2010, 6:146-51.

17. Huang HC, Hillman DR, McArindle N: Control of OSA during automatic positive airway pressure titration in a clinical case series: predictors and accuracy of device download data. Sleep 2012, 35:1277-83A.

18. Vennelle M, White S, Riha RL, Mackay TW, Engleman HM, Douglas NJ: Randomized controlled trial of variable-pressure versus fixed-pressure continuous positive airway pressure (CPAP) treatment for patients with obstructive sleep apnea/ hypopnea syndrome (OSAHS). Sleep 2010, 33:267-71.

19. Kushida CA, Berry RB, Blau A, Crabtree T, Fietze I, Kryger MH, Kuna ST, Peggam GV, Penzel P: Positive airway pressure airway pressure initiation: a randomized controlled trial to assess the impact of therapy mode and titration process on efficacy, adherence, and outcomes. Sleep 2011, 34:1083-92.

20. Skomro RP, Gjervé J, Reid J, McNab B, Ghosh S, Stiles M, Jokic R, Ward H, Cotson D: Outcomes of home-based diagnosis and treatment of obstructive sleep apnea. Chest 2010, 138:257-63.

21. Sparrow D, Aloia M, Demolles DA, Gottlieb DJ: A telemedicine intervention to improve adherence to continuous positive airway pressure: a randomised controlled trial. Thorax 2010, 65:1061–6.

22. Fox N, Hirsch-Allen AJ, Goodfellow E, Wenner J, Fleetham J, Ryan CF, Kwiatkowska M, Ayas NT: The impact of a telemedicine monitoring system on positive airway pressure adherence in patients with obstructive sleep apnea: a randomised controlled trial. Sleep 2012, 35:477-81.

23. Kanter MH, Lindsay G, Bellows J, Chase A: Complete care at Kaiser Permanente: transforming chronic and preventive care. Jt Comm J Qual Patient Saf 2013, 39:484-94.

24. Kushida CA, Morgenthaler TI, Littner MR, Alessi CA, Bailey D, Coleman J, Friedman L, Hirshkowitz M, Kapen S, Kramer M, Lee-Chiong T, Owens J, Pancer JP: Practice parameters for the treatment of snoring and Obstructive Sleep Apnea with oral appliances: an update for 2005. Sleep 2006, 29:40-3.

25. Phillips CL, Grunstein RR, Da rendeliler MA, Mihailidou AS, Srinivasan VK, Yee BJ, Marks GB, Cistulli PA: Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2013, 187:879-87.

26. Sutherland K, Vanderveken OM, Tsuda H, Marklund M, Gagnadoux F, Kushida CA, Cistulli PA: Oral Appliance Treatment for Obstructive Sleep Apnea: An Update. J Clin Sleep Med 2014, 10:215-27.

27. Ifukohar IH, Hays ER, Iversen M, Magalang UJ, Maas AK: Effect of oral appliances on blood pressure in obstructive sleep apnea: a systematic review and meta-analysis. J Clin Sleep Med 2013, 9:165-74.

28. Ferguson KA, Cartwright R, Rogers R, Schmidt-Nowara W: Oral appliances for snoring and obstructive sleep apnea: a review. J Clin Sleep Med 2009, 5:244-62.

29. Dort LC, Hadjuk E, Remmers JE: Mandibular advancement and obstructive sleep apnea: a method for determining effective mandibular protrusion. Eur Respir J 2006, 27:1003-9.

30. Remmers J, Charkhandeh S, Grosse J, Topor Z, Brant R, Santosham P, Bruehlmann S: Remotely controlled mandibular protrusion during sleep predicts therapeutic success with oral appliances.
in patients with obstructive sleep apnea. Sleep 2013, 36:1517-251525A.

31. Dietjens M, Braem MJ, Vroegop AVMT, Wouters K, Verbraecken JA, Backer WA de, van de Heyning PH, Vanderveken OM: Objective measured vs self-reported compliance during oral appliance therapy for sleep-disordered breathing. Chest 2013, 144:1495-502.

32. Smith YK, Verrett RG: Evaluation of a Novel Device for Measuring Patient Compliance with Oral Appliances in the Treatment of Obstructive Sleep Apnea. J Prosthodont 2014, 23:31-8.

33. Strollo PJ: Another advance in oral appliance therapy? Sleep 2013, 36:1417-8.

34. Rosenthal L, Massie CA, Dolan DC, Loomas B, Kram J, Hart RW: A multicenter, prospective study of a novel nasal EPAP device in the treatment of obstructive sleep apnea: efficacy and 30-day adherence. J Clin Sleep Med 2009, 5:532-7.

35. Colrain IM, Brooks S, Black J: A pilot evaluation of a nasal expiratory resistance device for the treatment of obstructive sleep apnea. J Clin Sleep Med 2008, 4:426-33.

36. Berry RB, Kryger MH, Massie CA: A novel nasal expiratory positive airway pressure (EPAP) device for the treatment of obstructive sleep apnea: a randomized controlled trial. Sleep 2011, 34:479-85.

37. Kryger MH, Berry RB, Massie CA: Long-term use of a nasal expiratory positive airway pressure (EPAP) device as a treatment for obstructive sleep apnea (OSA). J Clin Sleep Med 2011, 7:449-53B.

38. Rossé VA, Winter B, Rahman NM, Yu L, Fallon J, Clarenbach CF, Bloch KE, Stradling JR, Kohler M: The effects of Provent on moderate to severe obstructive sleep apnoea during continuous positive airway pressure therapy withdrawal: a randomised controlled trial. Thorax 2013, 68:854-9.

39. Braga CW, Chen Q, Burschtein OE, Rapoport DM, Ayappa I: Changes in lung volume and upper airway using MRI during application of nasal expiratory positive airway pressure in patients with sleep-disordered breathing. J Appl Physiol 2011, 111:1460-9.

40. Farid-Moayer M, Siegel LC, Black J: Oral pressure therapy for treatment of obstructive sleep apnea: clinical feasibility. Nat Sci Sleep 2013, 5:53-9.

41. Colrain IM, Black J, Siegel LC, Bogan RK, Becker PM, Farid-Moayer M, Goldberg R, Lankford DA, Goldberg AN, Malhotra A: A multicenter evaluation of oral pressure therapy for the treatment of obstructive sleep apnea. Sleep Med 2013, 14:830-7.

42. Aurora RN, Casey KR, Kristo D, Auerbach S, Bista SR, Chowdhuri S, Karpopp A, Lann C, Ramar K, Zak R, Morgenthaler TI: Practice parameters for the surgical modifications of the upper airway for obstructive sleep apnea in adults. Sleep 2010, 33:i408-13.

43. Schwartz AR, Smith PL, Oliven A: Electrical stimulation of the hypoglossal nerve: a potential therapy. J Appl Physiol 2014, 116:337-44.

44. Strollo PJ, Soose RJ, Maurer JT, Vries N de, Cornelius J, Froymovic M, Hinson RD, Paithya TA, Steward DL, Gillespie MB, Woodward BT, van de Heyning PH, Goetzting MG, Vanderveken OM, Feldman N, Knaack L, Strohl KP: Upper-airway stimulation for obstructive sleep apnea. N Engl J Med 2014, 370:139-49.

45. Kezirian EJ, Goding GS, Malhotra A, O’Donoghue FJ, Zammit G, Wheatley JR, Catcheseide PG, Smith PL, Schwartz AR, Walsh JH, Maddison KJ, Claman DM, Huntley T, Park SY, Campbell MC, Palme CE, Iber C, Eastwood PR, Hillman DR, Barnes M: Hypoglossal nerve stimulation improves obstructive sleep apnea: 12-month outcomes. J Sleep Res 2014, 23:77-83.

46. Malhotra A: Hypoglossal-nerve stimulation for obstructive sleep apnea. N Engl J Med 2014, 370:170-1.

47. Foster GD, Borradalle KE, Sanders MH, Millman R, Zammit G, Newman AB, Wadden TA, Kelley D, Wing RR, Pi-Sunyer FX, Reboussin D, Kuna ST: A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009, 169:1619-26.

48. Johansson K, Hemmingsson E, Harlid R, Trolle Lagerros Y, Granath F, Rössner S, Neovius M: Longer term effects of very low energy diet on obstructive sleep apnoea in cohort derived from randomised controlled trial: prospective observational follow-up study. BMJ 2011, 342:d3017.

49. Thomasouli M, Brady EM, Davies MJ, Hall AP, Khunti K, Morris DH, Gray LJ: The impact of diet and lifestyle management strategies for obstructive sleep apnoea in adults: a systematic review and meta-analysis of randomised controlled trials. Sleep Breath 2013, 17:925-35.

50. Greenburg DL, Lettieri CJ, Eliasson AH: Effects of surgical weight loss on measures of obstructive sleep apnea: a meta-analysis. Am J Med 2009, 122:535-42.

51. Fredheim JM, Rollheim J, Sandbu R, Hofso D, Omland T, Reislien J, Hjelmesæth J: Obstructive sleep apnea after weight loss: a clinical trial comparing gastric bypass and intensive lifestyle intervention. J Clin Sleep Med 2013, 9:427-32.

52. Sarkhosh K, Switzer NJ, El-Hadi M, Birch DW, Shi X, Karmali S: The impact of bariatric surgery on obstructive sleep apnea: a systematic review. Obes Surg 2013, 23:414-23.

53. Edholm D, Svensson F, Näslund I, Karlsson FA, Rask E, Sundbom M: Long-term results 11 years after primary gastric bypass in 384 patients. Surg Obes Relat Dis 2013, 9:708-13.